People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elucida Oncology, Inc. | — | Biotechnology | Series B | $117.1M | $255.6M | 2017 |
| Marina Biotech, Inc. | — | Pharmaceuticals | Series C | $69.2M | $113.7M | 2018 |
Tim A. Boris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tim A. Boris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac A. Blech | 2 | 3 |
| Tim Boris | 2 | 3 |
| Michael Smith | 1 | 20 |
| Isaac Blech | 1 | 14 |
| Robert Ruffolo | 1 | 8 |
| Michael T. Smith | 1 | 5 |
| Vuong Trieu | 1 | 5 |
| R. John Fletcher | 1 | 4 |
| Gary Sender | 1 | 3 |
| Robert Essner | 1 | 3 |
| Peter D. Parker | 1 | 3 |
| ULI HACKSELL | 1 | 3 |
| Michael D. Taylor | 1 | 2 |
| Chiang J. Li | 1 | 2 |
| Issac Blech | 1 | 2 |
| Gregory M. Sessler | 1 | 2 |
| Philippe A. Calais | 1 | 2 |
| Donald A. Williams | 1 | 2 |
| Nancy Phelan | 1 | 2 |
| Peter S. Garcia | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.